Treatment-related dysgeusia in head and neck cancer patients

Irune, Ekpemi; Dwivedi, Raghav C.; Nutting, Christopher M.; Harrington, Kevin

doi:10.1016/j.ctrv.2014.06.011

Cited by 68 publications

(62 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[11,35,[38][39][40] The prevalence among the patient receiving a combination of both radiotherapy and chemotherapy was 76%, radiotherapy only was 66.5%, radiotherapy of head and neck cancer was 55 to 88%, after completion of radiotherapy continue dysgeusia was 15% and chemotherapy only was 56.3%. [10,18,[41][42][43][44] Most of the studies were done in head and neck cancer and breast cancer but it is not possible from this review to conclude which cancer or treatment regimen has more effect on taste. Some of the papers suggests that the dose of radiotherapy and choice of drug for chemotherapy might have negative effect on taste change.…”

Section: Prevalence Of Dysgeusiamentioning

confidence: 99%

“…[8] Taste disorders are the major cause of malnutrition in the cancer patient, but it has been understudied and poorly addressed by health care professionals in the oncology setting. [1,9,10] Taste is an important sensation that serves to evaluate the nutritious content of food, supports oral intake and prevents ingestion of potentially toxic substances. [2] Research suggests that patients with taste loss had a worse outcome than those that did not lose their sense of taste and were able to maintain their food intake and nutritional support.…”

Section: Introductionmentioning

confidence: 99%

“…The dose of these treatments has to be well evaluated and kept to a minimal effective dose to avoid the side effects. [1,10,18] Sporadic research has been carried out to investigate the prevention and treatment of the taste changes related to cancer and its treatment. The aim of this review is to investigate pharmacological and behavioral management strategies for the prevention and management of taste alteration caused by cancer and its treatment in adult cancer survivors.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Management of Dysgeusia related to Cancer

Munankarmi

2017

J Lumbini Med Coll

View full text Add to dashboard Cite

a ----------------------------------------------- ABSTRACT:Introduction: Taste change due to cancer is a notorious side effect, adversely affecting appetite and weight. Even though taste change or dysgeusia is one of the major causes of poor nutritional status in cancer survivors, it is not addressed as a significant problem and is often left untreated. The main purpose of this review is to explore current knowledge of pharmacological and behavioral interventions for the treatment of cancer related taste change. Methods: This systematic review was conducted in accordance with PRISMA guidelines to identify original articles on taste change. Multiple databases including; Scopus, Medline, EMBASE, CINAHL, and all databases via Pro quest were searched for original articles or studies related to taste change caused by cancer or its treatment. Relevant articles were subjected to a full text evaluation and assessed by Critical appraisal skills program (CASP) guidelines and the Effective public health practice project (EPHPP) instrument. Results: The search revealed 12 eligible studies, six of which were randomized controlled trials. Most of the studies used a standardized validated tool to measure taste change. Dysgeusia is common in cancer, 14 to 100% cancer patient report it. Pharmacological management with zinc remains inconclusive as one study reports it as beneficial and two other studies reported null effect. Few studies suggested dietary modifications such as use of sugary, salty foods that are helpful to reduce the effect of dysgeusia. Conclusion: Dietary counseling and informing the patient well about self-care strategies before treatment has consistently shown positive results on taste change, with strong statistical power. Other potential treatments for dysgeusia such as zinc, amifostine, and megestrol acetate gave inconsistent results.

show abstract

Section: Prevalence Of Dysgeusiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of Dysgeusia related to Cancer

Munankarmi

2017

J Lumbini Med Coll

View full text Add to dashboard Cite

show abstract

“…In fact, up to 88% experience transient dysgeusia. 18 and 36% suffer radiation-induced nausea and vomiting of grade 2 or worse. 19 In addition, high-grade mucositis with concomitant weight loss is worse in HPV-related OPSCC compared with HPV-negative OPSCC.…”

Section: Morbidity Of Treatment Of Hpv-related Opsccmentioning

confidence: 99%

“…22 and more than 27% experience loss of one or more taste modalities after radiation therapy. 18 Recent advances in transoral surgical techniques have allowed upfront surgical resection to again play a role in the management of patients with oropharyngeal cancer. In these situations, with the primary tumor and the involved and at risk lymph node basins removed, a lower dose of adjuvant radiation or chemoradiation can be provided in an effort to decrease treatment-related side effects.…”

Section: Morbidity Of Treatment Of Hpv-related Opsccmentioning

confidence: 99%

Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines

Ward

Mehta

Moore

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Objective: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) related to human papillomavirus (HPV) is increasing at a dramatic rate, with men affected more commonly than women. Individuals who develop this disease suffer significant morbidity and potential mortality from their cancer and its associated treatment. We aim to evaluate the possible impact that the currently available HPV vaccines will have on this group of cancers. Data sources: Available peer-reviewed literature, practice guidelines, and statistics published by the Center for Disease Control and Prevention. Review methods: Contemporary peer-reviewed medical literature was selected based on its scientific validity and relevance to the impact HPV vaccination may have on the morbidity, mortality and cost resulting from HPV-related OPSCC in the United States. Conclusions: The incidence of HPV-related OPSCC is increasing at a near epidemic rate in the United States. The cost of treatment of HPV-related OPSCC is high, and the disease and its therapy result in significant morbidity and potential mortality to individuals. Using a cut-off of $50,000/Quality-Adjusted Life Year, expansion of current HPV vaccine indications to include prevention of OPSCC in both men and women should be recommended. IntroductionThe oropharynx is the area of the upper aerodigestive tract located behind the oral cavity and above the larynx. The oropharyngeal subsites include the soft palate, posterior pharyngeal wall, tongue base, and paired tonsillar fossae. The latter 2 subsites contain lymphoid tissue in the form of lingual and palatine tonsils, respectively, and these are the areas primarily affected by human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC).The oropharynx plays a critical role in many functions including swallowing, speech, and the maintenance of a patent airway. When affected by cancer or the sequelae of cancer therapy, these functions can be impaired, resulting in significant detriment to quality of life.

show abstract